QQQ3.55%

Trending

NBIS13.38%

home Symbol ACXPnews

ACXPAcurx Pharmaceuticals Inc

$1.65

$0.05

(3.13%)

Today

Closed $1.65

$0.0482

(2.92%)

After Hours

Updated: 04:37 PM EDT

EarningsAug 12

Mkt Cap$6.88M

Vol55,962.00

Fundamentals

Mkt Cap

$6.88M

Volume

52W High

$21.00

52W Low

$1.33

PE Ratio

-0.37

Avg. Volume

111,660.55

EPS (Annual)

-$5.32

Rev/Employee

$0.00

Earnings

Aug 12

Info

News

all

press releases

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks

More News

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update PR Newswire...

PR Newswire

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026 Acurx Announces Scientific Poster Presentation of its DNA pol IIIC...

PR Newswire

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase PR Newswire STATEN ISLAND, N.Y., April 29, 2026 STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire...

PR Newswire

Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update

Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results...

PR Newswire

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire STATEN ISLAND...

PR Newswire

Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct...

PR Newswire

Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.

Zacks

Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors PR...

PR Newswire

Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks

...

Advertisement|Remove ads.